New Publication Links Genetic Variants to Renal Risk in Cirrhosis

A new study was published on September 18, 2026 in The Lancet Gastroenterology & Hepatology. The publication, titled "Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association study," presents a genome-wide association study examining genetic factors tied to renal impairment in patients with decompensated cirrhosis. Terlipressin is an approved treatment relevant to this patient population, as it is used in the management of certain complications associated with decompensated cirrhosis. The publication is identified by PubMed ID 42759531 and is indexed for public access. No findings, outcomes, or conclusions from the study are detailed here beyond confirmation that the paper has been published. Readers interested in the specific genetic variants identified, the study population, or the multi-ancestry methodology should consult the full text directly through the journal or PubMed listing. This brief serves only to note the existence and basic bibliographic details of the publication, including its title, journal, and publication date. For more background on terlipressin, including its approved uses and general profile, readers can refer to the compound overview.